Laboratory of Molecular Gerontology, Biomedical Research Center, National Institute on Aging, NIH, IRP, 251 Bayview Boulevard, Baltimore, MD 21224, USA
Cell Mol Life Sci. 2010 Nov;67(21):3621-31. doi: 10.1007/s00018-010-0488-2. Epub 2010 Aug 31.
APE1 is a multifunctional protein that possesses several nuclease activities, including the ability to incise at apurinic/apyrimidinic (AP) sites in DNA or RNA, to excise 3'-blocking termini from DNA ends, and to cleave at certain oxidized base lesions in DNA. Pre-clinical and clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites. In an effort to improve the efficacy of therapeutic compounds, such as temozolomide, groups have begun to develop high-throughput screening assays and to identify small molecule inhibitors against APE1 repair nuclease activities. It is envisioned that such inhibitors will be used in combinatorial treatment paradigms to enhance the efficacy of DNA-interactive drugs that introduce relevant cytotoxic DNA lesions. In this review, we summarize the current state of the efforts to design potent and selective inhibitors against APE1 AP site incision activity.
APE1 是一种多功能蛋白,具有多种核酸酶活性,包括在 DNA 或 RNA 的无嘌呤/无嘧啶(AP)位点切割、从 DNA 末端切除 3'-封锁末端以及在 DNA 中的某些氧化碱基损伤处切割的能力。临床前和临床数据表明 APE1 在癌症发病机制和对 DNA 相互作用药物的耐药性中起作用,特别是单功能烷化剂和抗代谢物。为了提高治疗化合物(如替莫唑胺)的疗效,研究小组已开始开发高通量筛选测定法,并鉴定针对 APE1 修复核酸酶活性的小分子抑制剂。人们设想,这些抑制剂将用于联合治疗方案中,以增强引入相关细胞毒性 DNA 损伤的 DNA 相互作用药物的疗效。在这篇综述中,我们总结了设计针对 APE1 AP 位点切割活性的有效和选择性抑制剂的最新进展。